Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum
In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the cont...
Gespeichert in:
Veröffentlicht in: | Analytical methods 2024-06, Vol.16 (23), p.372-3731 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3731 |
---|---|
container_issue | 23 |
container_start_page | 372 |
container_title | Analytical methods |
container_volume | 16 |
creator | Cao, Rongrong Xu, Songlin Yu, Zhirui Xu, Liang Ge, Zhiqiang Huo, Qianyu Zhu, Guoqing Qiao, Bin |
description | In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g
−1
. The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL
−1
range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios.
Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum. |
doi_str_mv | 10.1039/d4ay00433g |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38808588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3067382814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c226t-5b4f07ebed00292cec93e2f26acf0c7c5e349147d02a50b5253934eb6ca9bc5c3</originalsourceid><addsrcrecordid>eNpd0UtP3DAQB3ALFcFCe-FOZakXhBTwIw_7iLa8pEU9bHvoKbKdyWKUxFnbUbt8BD412V1YJE4z0vw0o9EfoRNKLijh8rJK1YqQlPPFHprQIpOJzAv5Zdfn5BAdhfBESC55Tg_QIReCiEyICXq57yIsvIrWddjVuPcugu3wLLFt67Rt7DNUGHr3f4VbteggWoM1qAob1cfBA_5n4yOeTZOH-eXDHNfO4_gIXvUwrGnrOmca16kGqy5a7aoVXg7rtrZme3W8FsAP7Ve0X6smwLe3eoz-3Fz_nt4ls1-399OrWWIYy2OS6bQmBWioCGGSGTCSA6tZrkxNTGEy4KmkaVERpjKiM5ZxyVPQuVFSm8zwY3S23Tv-uhwgxLK1wUDTqA7cEEpOcloILigf6Y9P9MkNfnxmowoumKDpqM63yngXgoe67L1tlV-VlJTrhMqf6dXfTUK3I_7-tnLQLVQ7-h7JCE63wAezm35EzF8B0H6XrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067382814</pqid></control><display><type>article</type><title>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</title><source>MEDLINE</source><source>Royal Society Of Chemistry Journals 2008-</source><creator>Cao, Rongrong ; Xu, Songlin ; Yu, Zhirui ; Xu, Liang ; Ge, Zhiqiang ; Huo, Qianyu ; Zhu, Guoqing ; Qiao, Bin</creator><creatorcontrib>Cao, Rongrong ; Xu, Songlin ; Yu, Zhirui ; Xu, Liang ; Ge, Zhiqiang ; Huo, Qianyu ; Zhu, Guoqing ; Qiao, Bin</creatorcontrib><description>In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g
−1
. The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL
−1
range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios.
Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.</description><identifier>ISSN: 1759-9660</identifier><identifier>ISSN: 1759-9679</identifier><identifier>EISSN: 1759-9679</identifier><identifier>DOI: 10.1039/d4ay00433g</identifier><identifier>PMID: 38808588</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Acceptance criteria ; Animals ; Antibodies, Monoclonal - blood ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacokinetics ; Chromatography, Liquid - methods ; Coefficient of variation ; Humans ; IgG antibody ; Immunoglobulin G ; Immunomagnetic Separation - methods ; Intravenous administration ; Liquid chromatography ; Liquid Chromatography-Mass Spectrometry ; Mass spectrometry ; Mass spectroscopy ; Mice ; Microspheres ; Monoclonal antibodies ; Pembrolizumab ; Pharmacodynamics ; Pharmacokinetics ; Polymethacrylic Acids - chemistry ; Protein L ; Protein purification ; Proteins ; Purification ; Rituximab ; Tandem Mass Spectrometry - methods</subject><ispartof>Analytical methods, 2024-06, Vol.16 (23), p.372-3731</ispartof><rights>Copyright Royal Society of Chemistry 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c226t-5b4f07ebed00292cec93e2f26acf0c7c5e349147d02a50b5253934eb6ca9bc5c3</cites><orcidid>0000-0002-2731-2018 ; 0000-0002-8297-3353 ; 0000-0003-2210-476X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38808588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Rongrong</creatorcontrib><creatorcontrib>Xu, Songlin</creatorcontrib><creatorcontrib>Yu, Zhirui</creatorcontrib><creatorcontrib>Xu, Liang</creatorcontrib><creatorcontrib>Ge, Zhiqiang</creatorcontrib><creatorcontrib>Huo, Qianyu</creatorcontrib><creatorcontrib>Zhu, Guoqing</creatorcontrib><creatorcontrib>Qiao, Bin</creatorcontrib><title>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</title><title>Analytical methods</title><addtitle>Anal Methods</addtitle><description>In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g
−1
. The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL
−1
range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios.
Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.</description><subject>Acceptance criteria</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - blood</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Chromatography, Liquid - methods</subject><subject>Coefficient of variation</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Immunoglobulin G</subject><subject>Immunomagnetic Separation - methods</subject><subject>Intravenous administration</subject><subject>Liquid chromatography</subject><subject>Liquid Chromatography-Mass Spectrometry</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Mice</subject><subject>Microspheres</subject><subject>Monoclonal antibodies</subject><subject>Pembrolizumab</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Polymethacrylic Acids - chemistry</subject><subject>Protein L</subject><subject>Protein purification</subject><subject>Proteins</subject><subject>Purification</subject><subject>Rituximab</subject><subject>Tandem Mass Spectrometry - methods</subject><issn>1759-9660</issn><issn>1759-9679</issn><issn>1759-9679</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0UtP3DAQB3ALFcFCe-FOZakXhBTwIw_7iLa8pEU9bHvoKbKdyWKUxFnbUbt8BD412V1YJE4z0vw0o9EfoRNKLijh8rJK1YqQlPPFHprQIpOJzAv5Zdfn5BAdhfBESC55Tg_QIReCiEyICXq57yIsvIrWddjVuPcugu3wLLFt67Rt7DNUGHr3f4VbteggWoM1qAob1cfBA_5n4yOeTZOH-eXDHNfO4_gIXvUwrGnrOmca16kGqy5a7aoVXg7rtrZme3W8FsAP7Ve0X6smwLe3eoz-3Fz_nt4ls1-399OrWWIYy2OS6bQmBWioCGGSGTCSA6tZrkxNTGEy4KmkaVERpjKiM5ZxyVPQuVFSm8zwY3S23Tv-uhwgxLK1wUDTqA7cEEpOcloILigf6Y9P9MkNfnxmowoumKDpqM63yngXgoe67L1tlV-VlJTrhMqf6dXfTUK3I_7-tnLQLVQ7-h7JCE63wAezm35EzF8B0H6XrQ</recordid><startdate>20240613</startdate><enddate>20240613</enddate><creator>Cao, Rongrong</creator><creator>Xu, Songlin</creator><creator>Yu, Zhirui</creator><creator>Xu, Liang</creator><creator>Ge, Zhiqiang</creator><creator>Huo, Qianyu</creator><creator>Zhu, Guoqing</creator><creator>Qiao, Bin</creator><general>Royal Society of Chemistry</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QO</scope><scope>7QQ</scope><scope>7SE</scope><scope>7SR</scope><scope>7U5</scope><scope>8BQ</scope><scope>8FD</scope><scope>FR3</scope><scope>H8G</scope><scope>JG9</scope><scope>L7M</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2731-2018</orcidid><orcidid>https://orcid.org/0000-0002-8297-3353</orcidid><orcidid>https://orcid.org/0000-0003-2210-476X</orcidid></search><sort><creationdate>20240613</creationdate><title>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</title><author>Cao, Rongrong ; Xu, Songlin ; Yu, Zhirui ; Xu, Liang ; Ge, Zhiqiang ; Huo, Qianyu ; Zhu, Guoqing ; Qiao, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c226t-5b4f07ebed00292cec93e2f26acf0c7c5e349147d02a50b5253934eb6ca9bc5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acceptance criteria</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - blood</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Chromatography, Liquid - methods</topic><topic>Coefficient of variation</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Immunoglobulin G</topic><topic>Immunomagnetic Separation - methods</topic><topic>Intravenous administration</topic><topic>Liquid chromatography</topic><topic>Liquid Chromatography-Mass Spectrometry</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Mice</topic><topic>Microspheres</topic><topic>Monoclonal antibodies</topic><topic>Pembrolizumab</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Polymethacrylic Acids - chemistry</topic><topic>Protein L</topic><topic>Protein purification</topic><topic>Proteins</topic><topic>Purification</topic><topic>Rituximab</topic><topic>Tandem Mass Spectrometry - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Rongrong</creatorcontrib><creatorcontrib>Xu, Songlin</creatorcontrib><creatorcontrib>Yu, Zhirui</creatorcontrib><creatorcontrib>Xu, Liang</creatorcontrib><creatorcontrib>Ge, Zhiqiang</creatorcontrib><creatorcontrib>Huo, Qianyu</creatorcontrib><creatorcontrib>Zhu, Guoqing</creatorcontrib><creatorcontrib>Qiao, Bin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Copper Technical Reference Library</collection><collection>Materials Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Analytical methods</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Rongrong</au><au>Xu, Songlin</au><au>Yu, Zhirui</au><au>Xu, Liang</au><au>Ge, Zhiqiang</au><au>Huo, Qianyu</au><au>Zhu, Guoqing</au><au>Qiao, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum</atitle><jtitle>Analytical methods</jtitle><addtitle>Anal Methods</addtitle><date>2024-06-13</date><risdate>2024</risdate><volume>16</volume><issue>23</issue><spage>372</spage><epage>3731</epage><pages>372-3731</pages><issn>1759-9660</issn><issn>1759-9679</issn><eissn>1759-9679</eissn><abstract>In recent years, there has been a growing interest in the thriving monoclonal antibody (mAb) industry due to the wide utilization of mAbs in clinical therapies. Robust and accurate bioanalytical methods are required to enable fast quantification of mAbs in biological matrices, especially in the context of pharmacokinetics (PKs)/pharmacodynamics (PDs) and therapeutic drug monitoring (TDM) studies. In this investigation, we presented a novel immuno-magnetic capture coupled with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method designed for the quantification of immunoglobulin G-kappa-based mAbs in biological fluids. The immunoaffinity absorbent for mAb drug purification was meticulously crafted by immobilizing protein L onto monosize, magnetic poly(glycidyl methacrylate) (m-pGMA) beads, synthesized through dispersion polymerization. The microspheres were acquired with an average size of 1.6 μm, and the optimal binding of mAbs from the aqueous mAb solution was determined to be 45.82 mg g
−1
. The quantification of mAbs in 10 μL serum samples was achieved through affinity purification using m-pGMA@protein L beads (employing rituximab as an internal standard (IS)), on-bead reduction, and rapid tryptic digestion. Remarkably, the entire process, taking less than 2.5 hours, held significant potential for simplifying pretreatment procedures and minimizing analytical time. Furthermore, the developed method underwent validation in accordance with the European Medicines Agency (EMA) guidelines. The assay demonstrated commendable linearity within the 2-400 μg mL
−1
range for both daratumumab and pembrolizumab. Intra- and inter-assay coefficients of variation fell within the range of 0.7% to 13.4%, meeting established acceptance criteria. Other validation parameters also conformed to regulatory standards. Ultimately, the efficacy of the method was substantiated in a pharmacokinetic study following a single-dose intravenous administration to mice, underscoring its applicability and reliability in real-world scenarios.
Procedures for integrating protein L-immobilized magnetic bead capture with LC-MS/MS for mAb quantification in mouse serum.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>38808588</pmid><doi>10.1039/d4ay00433g</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2731-2018</orcidid><orcidid>https://orcid.org/0000-0002-8297-3353</orcidid><orcidid>https://orcid.org/0000-0003-2210-476X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1759-9660 |
ispartof | Analytical methods, 2024-06, Vol.16 (23), p.372-3731 |
issn | 1759-9660 1759-9679 1759-9679 |
language | eng |
recordid | cdi_pubmed_primary_38808588 |
source | MEDLINE; Royal Society Of Chemistry Journals 2008- |
subjects | Acceptance criteria Animals Antibodies, Monoclonal - blood Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacokinetics Chromatography, Liquid - methods Coefficient of variation Humans IgG antibody Immunoglobulin G Immunomagnetic Separation - methods Intravenous administration Liquid chromatography Liquid Chromatography-Mass Spectrometry Mass spectrometry Mass spectroscopy Mice Microspheres Monoclonal antibodies Pembrolizumab Pharmacodynamics Pharmacokinetics Polymethacrylic Acids - chemistry Protein L Protein purification Proteins Purification Rituximab Tandem Mass Spectrometry - methods |
title | Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A06%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Integration%20of%20protein%20L-immobilized%20epoxy%20magnetic%20bead%20capture%20with%20LC-MS/MS%20for%20therapeutic%20monoclonal%20antibody%20quantification%20in%20serum&rft.jtitle=Analytical%20methods&rft.au=Cao,%20Rongrong&rft.date=2024-06-13&rft.volume=16&rft.issue=23&rft.spage=372&rft.epage=3731&rft.pages=372-3731&rft.issn=1759-9660&rft.eissn=1759-9679&rft_id=info:doi/10.1039/d4ay00433g&rft_dat=%3Cproquest_pubme%3E3067382814%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067382814&rft_id=info:pmid/38808588&rfr_iscdi=true |